Alafair Biosciences
Austin, US · Founded 2011 · Delaware corporation · 3 known investors
Find your way into Alafair Biosciences
596 people in our graph share verified history with the Alafair Biosciences team — schools, employers, funds. One of them is your warm intro.
Viswa Sankaranarayananunlockedknows John Joyoprayitno · together at The University of Texas at Austin (overlapped)
×9knows the team · via The University of Texas at Austin
knows the team · via Texas McCombs School of Business
knows the team · via University of Michigan College of Engineering
Alafair Biosciences develops advanced bioresorbable biomaterials for surgical soft tissue healing and motion preservation. The company serves surgeons and patients undergoing procedures requiring post-surgical recovery, with a focus on preventing tissue tethering and supporting natural mobility.
Founders & leadership
Alafair Biosciences was founded in 2011 by Sarah Mayes.
SM
Sarah MayesinChief Scientific Officer and Co-founderSarah Mayes holds a PhD in biomedical engineering from UT-Austin and an MS in material science & engineering from the University of Michigan, Ann Arbor. She is co-founder and Chief Scientific Officer of Alafair Biosciences, where she oversees clinical, R&D, quality assurance, product development, and manufacturing for the company's bioresorbable biomaterials used in surgical soft tissue repair.
DP
Daniel PetersoninCEO2011–2016Daniel Peterson is a neurosurgeon with private practice in Austin since 1994 and Chief Medical Officer and Chairman of Alafair Biosciences, where he has held leadership roles since 2011. He has served as Chief of Surgery at The Hospitals at Westlake and consulted for multiple medical device and biotech companies.
JJ
John JoyoprayitnoinPresident & CEO/ Co-founderJohn Joyoprayitno is President and CEO of Alafair Biosciences, which develops bioresorbable biomaterials for surgical soft tissue healing. He brings over 20 years of experience in medical device leadership and entrepreneurship, holds a Master of Science in Technology Commercialization from the McCombs School of Business at the University of Texas at Austin, and earned a Bachelor of Arts in Anthropology from the same institution.
Board
JD
RW
Robert WillsBoard director
CL
Christophe LavigneBoard director
JB
John B. Henneman, IIIBoard director
JP
James P. FellerBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$6M disclosed across 5 rounds · 2011–2018
▶$2.3MraisedOct 2018 · 15 investors · BiotechnologyRule 506(b)
▶$2.3MraisedOct 2018 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel PetersonDirector
- Jerry DeVriesDirector
- Mark BenedykDirector
- James Patrick FellerDirector
- Kyle A. CoxDirector
- John B. HennemanDirector
- John JoyoprayitnoExecutive Officer
- R. Gregory BrophyExecutive Officer
- Offering amount
- $6.8M
- Amount sold
- $2.3M
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$965KraisedJul 2017 · 9 investors · BiotechnologyRule 506(b)
▶$965KraisedJul 2017 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel PetersonDirector
- John B. HennemanDirector
- R. Gregory BrophyExecutive Officer
- John JoyoprayitnoExecutive Officer
- James Patrick FellerDirector
- Jerry DeVriesDirector
- Kyle A. CoxDirector
- Jim GamettDirector
- Offering amount
- $2M
- Amount sold
- $965K
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$984KraisedOct 2015 · 11 investors · BiotechnologyRule 506(b)
▶$984KraisedOct 2015 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert WillsDirector
- Daniel PetersonExecutive Officer, Director
- Jerry DeVriesDirector
- Christophe LavigneDirector
- John B. Henneman, IIIDirector
- James P. FellerDirector
- John JoyoprayitnoExecutive Officer
- Offering amount
- $2M
- Amount sold
- $984K
- First sale
- Oct 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$1MraisedMay 2014 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedMay 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christophe LavigneDirector
- Robert WillsDirector
- John JoyoprayitnoExecutive Officer
- Jerry DeVriesDirector
- Daniel PetersonExecutive Officer, Director
- James P. FellerDirector
- Offering amount
- $2M
- Amount sold
- $1M
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$702KraisedJan 2012 · 14 investors · BiotechnologyRule 506(b)
▶$702KraisedJan 2012 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James P. FellerDirector
- Daniel PetersonExecutive Officer, Director
- John JoyoprayitnoExecutive Officer
- Jerry DeVriesDirector
- Offering amount
- $1.5M
- Amount sold
- $702K
- First sale
- Nov 2011
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Alafair Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Alafair Biosciences do?
- Alafair Biosciences develops advanced bioresorbable biomaterials for surgical soft tissue healing and motion preservation. The company serves surgeons and patients undergoing procedures requiring post-surgical recovery, with a focus on preventing tissue tethering and supporting natural mobility.
- Who founded Alafair Biosciences?
- Alafair Biosciences was founded by Sarah Mayes in 2011.
- Who are Alafair Biosciences's investors?
- Alafair Biosciences's investors include ATP, TEXO Ventures, UT Horizon Fund.
- How much funding has Alafair Biosciences raised?
- Alafair Biosciences has disclosed $6M raised across 5 rounds.
- Where is Alafair Biosciences headquartered?
- Alafair Biosciences is headquartered in Austin, US.